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INTRODUCTION
Clinical practice guidelines (guidelines) have been a familiar 
part of  clinical practice for decades, but their importance 
and consequent proliferation worldwide is a more recent 
phenomenon. The increasing interest in guidelines is due 
to several health system factors – the need to cut costs, 
newer health care financing arrangements, variation in 
health service delivery mechanisms, and the transition of  
medicine toward more multidisciplinarity. Guidelines are 
often included in legal contracts between providers and 
purchasers due to the need to contain rising health‑care 
costs[1,2] and concerns about overuse of  interventions and 
investigations.[3] Guidelines thus are being used not only for 
clinical decision‑making but also as a standard framework 
for measuring quality of  care. Guidelines thus provide the 
technical basis for setting rules of  procedures for operation 
of  health facilities and clinics, define health‑care budgets, 
and spending, determination of  what costs should be 
reimbursed by insurers, formulating essential medicine 
lists, and influence pharmaceuticals‑related trade policies.
The increasing importance of  guidelines has meant that the 
recommendations within it, and consequently, the methods 
used to formulate these recommendations has come under 
increased scrutiny. In response, the concept of  guidelines 
and the way it is being developed has also evolved over 
time. The review discusses this evolution with a focus on 
the use of  evidence in the guideline development process 
and also provides an international overview of  guideline 
development process at the country level.
THE NEED FOR EVIDENCE IN DEVELOPING 
GUIDELINES
The modern history of  guidelines began in 1992, with the 
Institute of  Medicine, United States of  America (IOM, 
USA) published a report titled “Clinical Practice Guidelines: 
Directions for a New Program” which for the first time 
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formally defined guidelines.[4] This marked the beginning 
of  an era, where the profile of  guidelines increased 
exponentially owing to several health system issues. During 
this period, the number of  guidelines increases rapidly from 
just 374 indexed in MEDLINE in 1993 to 980 in 1996.[5] 
Even though the IOM, USA, document had noted the 
importance of  having a systematic process of  development 
of  clinical practice guidelines,[4] it continued to be based 
on expert opinions. Research indicated that the ability of  
a guideline to improve quality of  care and improve health 
system performance depended on several factors during 
the guideline development process. Expert opinions varied 
not only between different specialties of  expert clinicians 
but also from within clinicians of  the same specialty 
and between those clinicians who made guidelines and 
clinicians who actually implemented them.[6‑8] It was also 
found that the composition of  the guideline development 
group influenced the recommendations[9,10] and that the 
recommendations made by clinical experts were often 
in conflict with the best available research evidence.[11] A 
rigorous process of  identifying and evaluating research 
evidence and adapting them appropriately in a transparent 
manner with effective management of  conflict of  interests 
during the guideline development process[12,13] was thus 
found to be critical for a guideline to be able to provide 
a meaningful framework against which medical quality 
of  care can be measured and important health systems’ 
decisions be based on.
USE OF EVIDENCE FOR GUIDELINE 
DEVELOPMENT
The use of  research evidence for developing guidelines 
has its roots in of  two larger movements which took the 
world of  medicine and health care by storm since the 1990s.
The first of  these movements was a result of  the 
HIV/AIDS epidemic with the USA as it is the epicenter. 
HIV/AIDS activists in the USA constantly argued that 
clinical trials were not only sites for scientific activity but 
also sites for clinical care. However, an insurance‑based 
healthcare financing system in the USA meant coverage 
could be denied based on clinical practice guidelines. 
For activists, this implied that the focus of  their activity 
could no longer be restricted to demands for increased 
funding for research. The activists demanded greater say 
in understanding the use and interpretation of  research 
evidence to formulate recommendations for guidelines. 
Activists not only used their political power and took 
on professional societies, insurance companies to secure 
a place in drug development, regulation and guidelines 
development panels but also helped forge “new social 
relationships and identities, new institutions, and new facts 
and beliefs in the process.”[14] Activists were not only vocal 
about how their priorities were different from those of  
clinicians resulting in negative clinical outcomes but were 
also able to project themselves as credible participants in 
design, conduct, and interpretation of  clinical trials for 
formulating recommendations ‑ an arena that had always 
been exclusive for credentialed experts.[15]
Patient or lay participation in health care decision‑making 
had implications beyond AIDS as it broke the cultural 
authority health‑care professionals till then have been able 
to hold on to for centuries. It changed the dynamic of  the 
doctor‑patient relationship and blurred the boundaries 
between society and science.[14] This was a subtle but firm 
change in the guideline ecostructure as opinions of  experts 
were no longer taken for granted, even in matters which 
were technical in nature. It has changed the very nature 
of  what constitutes as being “credible” in health policy or 
guideline development process.
The evidence‑based medicine movement on both sides 
of  the Atlantic was the other movement which had a 
more profound and direct influence in advocating for the 
greater role of  evidence in guideline development and this 
continues till date. Although the roots of  evidence‑based 
medicine have been planted much[16] earlier the movement 
caught steam only in 1992 when researchers from Canada 
and USA collaborated with each other to form the 
evidence‑based medicine working group.[17] Across the 
Atlantic in United Kingdom, the Cochrane Collaboration 
was formed in 1993.[16] The practice of  evidence‑based 
medicine was described as “ integrating individual clinical 
expertise with the best available external clinical evidence 
from systematic research.”[18]
The requirement of  guideline panels to be objectively 
informed about the current status of  research evidence on 
efficacy and safety of  alternative health‑care interventions 
is well fulfilled by a systematic review. A systematic 
review systematically searches for all available research 
evidence (published or unpublished), critically evaluates 
the quality of  available evidence, and provides an evidence 
summary for a particular intervention in comparison to an 
alternative. The element of  transparency of  judgments used 
in critical appraisal of  quality of  evidence in a systematic 
review additionally allows guideline panels to make 
judgments about their utility and acceptability. In addition, 
systematic reviews by collating all evidence on a particular 
research question into a single study serves a practical 
purpose in the current age of  “information overload”[19] 
where it is impossible for any single health professional 
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to be updated of  all evidence. It also prevents any bias 
in selection of  individual studies for informing guideline 
development. Guideline panels use systematic reviews 
of  health‑care interventions, diagnostic tests, prognostic 
markers, cost‑effectiveness analyses, and even systematic 
reviews of  qualitative studies to understand values, 
perceptions, and preferences of  patients, health‑care staff, 
and policy makers to inform the guideline development 
process.
The influence of  these two movements in changing the 
concept of  guidelines has been reflected in the definition 
of  guidelines given by major international organizations 
over time and has been summarized in Table 1. Over time 
organizations had included the need for research evidence 
and later specifically inculcated the need for systematic 
reviews in informing the guideline development process 
in an objective and transparent manner. As, for example, 
in 2007, it was found that recommendations in the World 
Health Organization (WHO) guidelines were not based on 
systematic search and appraisal of  evidence but on expert 
opinions.[26] In response to the ensuing public outcry, 
the WHO responded by developing a Guideline Review 
Committee to implement and oversee quality assurance 
mechanisms for guideline development. A follow‑up 
evaluation in 2013 found that the quality of  WHO 
guidelines have improved[27] on several counts.
The use of  evidence in the form of  systematic reviews is 
now considered as a standard internationally for guideline 
development. However, systematic reviews do not provide 
any information on how much confidence can be placed 
on a recommendation made on the basis of  the evidence 
from the systematic review and how applicable it might 
be in a particular setting and how well it aligns to health 
systems values and preferences. To overcome these issues, a 
system called Grading of  Recommendations: Assessment, 
Development, and Evaluation (GRADE) which enables a 
guideline panel to classify a recommendation as strong or 
weak based on a series of  sequential, explicit judgments to 
balance harms and benefits between alternative strategies, 
quality of  evidence, resource, and cost implications as well as 
variability in values and preferences[28] has been developed. 
The GRADE approach has been adopted by more than 
hundred organizations globally, including the WHO[25] and 
is now considered the standard for this purpose replacing 
the previous methods of  recommendations being based 
on quality or levels of  evidence only.
A key issue during guideline development, during 
formulation of  recommendations, is acquiring consensus 
among a diverse group of  individuals, often with competing 
interests and values. While moderated group discussions 
are commonly used, such an approach does not encourage 
equal inputs from all participants. The use of  formal 
Table 1: Evolution of definitions of guidelines over time in 
different organizations
Organisation 
year
Definition
IOM 1990 “Practice guidelines are systematically developed 
statements to assist practitioner and patient decisions 
about appropriate health care for specific clinical 
circumstances”[4]
NICE 2006 “NICE’s clinical guidelines are recommendations, based 
on the best available evidence, for the care of people by 
health‑care professionals. In general, clinical guidelines 
have been defined as “systematically developed 
statements to…. clinical circumstances,” (IOM 
definition) although they are also relevant to health 
service managers”[20]
WHO 2010 “A WHO guideline is any document containing 
recommendations about health interventions, 
whether these are clinical, public health, or policy 
recommendations. A recommendation provides 
information about what policy makers, health‑care 
providers or patients should do. It implies a choice 
between different interventions that have an impact 
on health and that have implications for the use of 
resources”[21]
IOM 2011 “Statements that include recommendations intended to 
optimize patient care that are informed by a systematic 
review of evidence and an assessment of the benefits 
and harms of alternative care options”[22]
NICE 2012 “NICE clinical guidelines are recommendations, based 
on the best available evidence, for the care of people by 
healthcare and other professionals. They are relevant to 
clinicians, health service managers, and commissioners 
as well as to patients and their families and carers”[23]
WHO 2012 The 2012 version kept the WHO 2010 definition but the 
section on definition in addition included the following
“WHO has adopted internationally recognized standards 
and methods for guideline development to ensure that 
guidelines are free from bias, meet a public health need 
and are consistent with the following principles
Recommendations are based on a comprehensive and 
objective assessment of the available evidence
The process used to develop the recommendations 
is clear. That is, the reader will be able to see how a 
recommendation has been developed, by whom, and on 
what basis”[21]
NICE 2014 “NICE guidelines make evidence‑based 
recommendations on a wide range of topics, from 
preventing and managing specific conditions, improving 
health, and managing medicines in different settings, to 
provide social care and support to adults and children, 
safe staffing, and planning broader services and 
interventions to improve the health of communities. 
They aim to promote individualized care and integrated 
care (for example, by covering transitions between 
children’s and adult services and between health and 
social care)”[24]
WHO 2014 The 2014 version built on the 2012 version to 
specifically note that
“WHO’s legitimacy and technical authority lie in its 
rigorous adherence to the systematic use of evidence 
as the basis for all policies”[25] and had an extensive list 
of nine guiding principles for its development
NICE: National Institute of Clinical Excellence, IOM: Institute of 
Medicine, WHO: World Health Organization
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procedures such as the Delphi technique or the nominal 
group technique are hence essential for ensuring guideline 
quality.[24,25]
ASSESSMENT OF QUALITY OF GUIDELINES
While there are several frameworks available to understand 
the quality of  guidelines, a conceptual framework to 
understand how guidelines impact health outcomes 
measured is presented in Figure 1. The framework, based on 
a 2001 report,[29] indicates that several key strategies during 
guideline development such as involvement of  health 
system actors, consideration of  context, and methodological 
rigor are essential for successful implementation of  
guidelines and consequential improvement in health 
outcomes.[1,30,31] Quality of  guidelines is thus appraised 
by evaluating strategies used in various parts of  the 
guideline development process. A review of  guidelines 
from 10 European countries and Canada[32] and 18 major 
guideline development program[33] by the Appraisal 
of  Guidelines, Research, and Evaluation (AGREE) 
collaboration led to the identification of  factors in the 
guideline development process which predicted the 
quality of  guidelines. Further research by the AGREE 
collaboration led to the development of  an instrument to 
measure the quality of  guidelines. It was called the AGREE 
tool and had 23 items to be graded on a 4‑point Likert 
scale.[34] The tool was well accepted internationally and 
was subsequently revised to improve usability, reliability, 
and validity for a revised version called AGREE II. The 
AGREE II tool has been tested and validated rigorously[35] 
and is used by several leading organizations including the 
WHO[25] to monitor the quality of  guidelines.
GUIDELINE DEVELOPMENT AT THE 
COUNTRY‑LEVEL
This section of  the review provides an international 
overview of  how guidelines are developed at the country 
level. It does not intent to exhaustively cover guideline 
development for all the countries of  the world but attempts 
to present the broad typologies of  how guidelines are being 
developed at the country level.
Countries with a central agency responsible for 
guideline development
Guideline development in these countries is the exclusive 
mandate of  a central agency. Countries which have adopted 
this model are all high‑income countries with a strong 
public health system providing universal health coverage. 
This ensures easier adoption and implementation of  a 
single guideline throughout the country. However, the 
statutory footing and level of  autonomy these centralized 
agencies enjoy are different in different countries.
National Institute for Health and Care Excellence (NICE) 
in England is funded fully by the Department of  
Health but is operationally independent of  the 
government.[36] The organization has a very detailed 
Figure 1: Conceptual framework to understand how guidelines improve health outcomes[29]
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manual on guideline development which details the process 
for guideline panel formation, stakeholder involvement, 
development of  evidence summaries, and formulation of  
recommendations.[24]
Scottish Intercollegiate Guidelines Network (SIGN), 
Scotland, is a part of  Healthcare Improvement 
Scotland, a government organization since 2005. The 
SIGN guidelines are prepared on the basis of  three 
principles ‑ multidisciplinary, nationally representative 
panels, identification and critical appraisal of  evidence 
through systematic reviews, and recommendations being 
exclusively linked with supporting evidence.[37] To prevent 
duplication of  efforts SIGN also adapts already existing 
NICE guidelines[38] using a tool for contextualizing 
guidelines called ADAPTE tool.[39]
The Finnish Medical Society Duodecim, which is entrusted 
with the responsibility of  developing guidelines, is not a 
public agency. It is the country’s largest scientific association. 
The guidelines, known as “current care guidelines,” are 
prepared by the Duodecim in a collaborative manner 
with various other medical specialist organizations but are 
funded publicly.[40] In Finland, guidelines are integrated with 
the evidence‑based medicine electronic decision support 
system, which allows health‑care professionals to open 
guidelines from within the electronic patient record thus 
enabling greater dissemination and uptake.
Quality of  guidelines in these countries is generally good 
and has improved over the years on account of  provision 
of  methodological training for guideline development as 
well as use of  the AGREE II tool as a benchmark for 
guideline development.[24,37] In England and Scotland 
(both under the United Kingdom), financial incentives 
are often used to facilitate guideline implementation.[41,42]
Countries with a centrally coordinated mechanism 
with multiple organizations involved in the guideline 
development process
To improve quality of  guidelines, some countries have 
adopted a different model wherein they have a centralized 
agency with the mandate to coordinate and endorse 
guidelines instead of  actually taking up the guideline 
development function. Countries which have adopted 
this model are high income countries and most of  them 
have a pluralistic health system. Any health system actor, 
be it a professional society or a public agency, can develop 
guidelines as per a preset standard and this has to be 
endorsed before implementation by the centralized agency. 
Prominent countries which use such a model are Germany, 
France, Australia, USA, and Canada. Governance, 
autonomy as well as regulatory frameworks are widely 
different in different countries.
In Germany, guidelines are developed by individual 
medical associations, but the process is coordinated and 
endorsed by the Association of  the Scientific Medical 
Societies in Germany (AWMF ‑ Arbeitsgemeinschaft der 
Wissenschaftlichen Medizinischen Fachgesellschaften), which is an 
umbrella organization of  all medical associations. AWMF 
is not publicly funded. AWMF also coordinates with the 
German Medical Association (Bundesärztekammer) and 
the National Association of  Statutory Health Insurance 
Physicians (Kassenärztliche Bundesvereinigung) to develop 
guidelines for disease covered under the publicly funded 
program called “Nationale Versorgungsleitlinien.”[43] These 
guidelines are mandatory in nature and can be used as the 
basis for malpractice litigations.
In France, the Haute Authorité de Sauté develops as well 
as approves guidelines developed by external agencies.[44] 
similar to what is being done in Germany.
Australia is slightly different from other countries because the 
National Health and Medical Research Council (NHRMC) 
performs a dual function of  developing guidelines for 
the government as well as approving guideline developed 
by others. NHRMC is a public agency and has a strong 
legislative footing through the NHRMC Act 1992.[45] Medical 
societies as well as provincial authorities and other agencies 
are free to develop their own guidelines as per the standards 
laid down by the NHRMC which scrutinizes and approves 
them before dissemination and implementation.[46]
In USA, guidelines are developed by several agencies and 
are submitted to the National Guideline Clearing House, an 
arm of  the Agency for Healthcare Research and Quality, for 
assessment as per its standard criteria.[47] The U.S. Preventive 
Services Task Force is a well‑recognized independent group 
which develops evidence‑based guidelines for preventive 
services such as screening tests, counseling, or preventive 
medications.[48] Canada too follows a model similar to USA 
in terms of  guideline development.
In most countries which fall under this bracket, quality of  
guidelines is good and either the AGREE II or its variants 
is used for quality control and the coordinating agency is 
usually involved in capacity building efforts.
Countries where multiple organizations develop 
guidelines with no mechanism for coordination
Most low‑ and middle‑income countries, including India, 
and few high income countries (such as Korea and 
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Singapore) fall under this bracket where a multitude of  
actors develop their own guidelines with no centralized 
agency to either coordinate or develop guidelines. An 
evaluation of  guidelines in South African countries had 
found that the quality of  guidelines was poor and it varied 
both within and between countries.[49] Nothing more is 
known about the quality of  guidelines or about the use of  
evidence in the guideline development process. There is a 
little commonality in the manner in which health systems 
are arranged in these diverse groups of  nations either.
Countries which do not develop their own guidelines
This group consists of  several low‑income countries, 
including some with political instability, which do not 
develop their own guidelines. Such countries are usually 
dependent on foreign aid and hence follow guidelines 
either developed by the WHO or any such as enforced 
by the donor. Almost nothing is known about quality of  
guidelines and guideline development in these countries or 
the suitability of  the guidelines being used for the country. 
Although the ADAPTE tool[39] is very suitable for use in 
such a context, its use at the country level is minimal if  at all 
and this has not been documented in the medical literature.
CONCLUSION
Guideline development has undergone changes in the last 
few years with the use of  research evidence, in the form 
of  systematic reviews in formulating recommendations 
becoming an acceptable global standard. Historically, 
several forces and health system issues have triggered this 
change. However, for most countries globally, where there 
is no formal organization or coordination on guideline 
development, and very little is known about processes being 
used for guideline development. The quality of  guidelines 
used in these countries, how evidence is used in formulating 
them and the barriers to uptake of  evidence are critical 
research gaps which need to be studied in the future. Such 
research can help facilitate understanding of  mechanisms 
that can be setup within different health systems for optimal 
development of  good quality guidelines which can lead to 
improved health outcomes.
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